Latest News in the pharma Industry

Research & Development

BMS and Lilly Set to Collaborate to Evaluate Opdivo in Combination with Galunisertib in Advanced Solid Tumours

BMS and Lilly Set to Collaborate to Evaluate Opdivo in Combination with Galunisertib in Advanced Solid Tumours

14 Jan 2015

Read more 
Amgen and MD Anderson Announce Agreement to Develop BiTE Therapies for Myelodysplastic Syndrome

Amgen and MD Anderson Announce Agreement to Develop BiTE Therapies for Myelodysplastic Syndrome

13 Jan 2015

Read more 
Isarna Therapeutics Unveils New Selective TGF-beta Antagonist Program Targeting Multiple Indications in Ophthalmology

Isarna Therapeutics Unveils New Selective TGF-beta Antagonist Program Targeting Multiple Indications in Ophthalmology

12 Jan 2015

Read more 
Seattle Genetics and BMS Announce Clinical Collaboration to Evaluate Combination of Adcetris and Opdivo in Hematologic Malignancies

Seattle Genetics and BMS Announce Clinical Collaboration to Evaluate Combination of Adcetris and Opdivo in Hematologic Malignancies

12 Jan 2015

Read more 
HemoShear to Collaborate with Pfizer to Help Identify and Predict Drug-Induced Vascular Injury for Early-Stage Compounds

HemoShear to Collaborate with Pfizer to Help Identify and Predict Drug-Induced Vascular Injury for Early-Stage Compounds

12 Jan 2015

Read more 
Regeneron and Sanofi Announce Positive Topline Results from First Phase III Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia

Regeneron and Sanofi Announce Positive Topline Results from First Phase III Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia

9 Jan 2015

Read more 
Alkermes Phase II Results of ALKS 3831 Antipsychotic/Lower Weight Gain for Schizophrenia

Alkermes Phase II Results of ALKS 3831 Antipsychotic/Lower Weight Gain for Schizophrenia

8 Jan 2015

Read more 
Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin Platform for Cancer Therapeutics

Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin Platform for Cancer Therapeutics

7 Jan 2015

Read more 
Vectura Signs Global Development and Licence Agreement with Janssen in Asthma/COPD

Vectura Signs Global Development and Licence Agreement with Janssen in Asthma/COPD

6 Jan 2015

Read more 
Bavarian Nordic Initiates Phase I Clinical Trial for the Ebola Vaccine Regimen of MVA-BN Filo and Janssen's AdVac Technology

Bavarian Nordic Initiates Phase I Clinical Trial for the Ebola Vaccine Regimen of MVA-BN Filo and Janssen's AdVac Technology

6 Jan 2015

Read more 
Amgen and Kite Pharma to Collaborate to Advance the Application of Novel Chimeric Antigen Receptor T Cell Therapies

Amgen and Kite Pharma to Collaborate to Advance the Application of Novel Chimeric Antigen Receptor T Cell Therapies

6 Jan 2015

Read more 
Highly Efficient Neural Transfection Reagent

Highly Efficient Neural Transfection Reagent

5 Jan 2015

Read more